Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot

Vinicius N de Brito, Ana C Latronico, Ivo J P Arnhold, Leonard S S Lo, Sorahia Domenice, Maria C C Albano, Maria C B V Fragoso, Berenice B Mendonca

Abstract
The gonadotropin releasing hormone (GnRH) secreting hypothalamic hamartoma (HH) is a congenital malformation consisting of a heterotopic mass of nervous tissue that contains GnRH neurosecretory neurons attached to the tuber cinereum or the floor of the third ventricle. HH is a well recognised cause of gonadotropin dependent precocious puberty (GDPP). Long term data are presented on eight children (five boys and three girls) with GDPP due to HH. Physical signs of puberty were observed before 2 years of age in all patients. At presentation with sexual precocity, the mean height standard deviation (SD) for chronological age was +1.60 (1.27) and the mean height SD for bone age was −0.92 (1.77). Neurological symptoms were absent at presentation and follow up. The hamartoma diameter ranged from 5 to 18 mm and did not change in six patients who had magnetic resonance imaging follow up. All patients were treated clinically with GnRH agonists (GnRH-a). The duration of treatment varied from 2.66 to 8.41 years. Seven of the eight children had satisfactory responses to treatment, shown by regression of pubertal signs, suppression of hormonal levels, and improvement of height SD for bone age and predicted height. One patient had a severe local reaction to GnRH-a with failure of hormonal suppression and progression of pubertal signs. It seems that HH is benign and that GnRH-a treatment provides satisfactory and safe control for most children with GDPP due to HH.

Keywords: hypothalamic hamartoma; gonadotropin releasing hormone agonist; precocious puberty

Gonadotropin dependent precocious puberty (GDPP) occurs as a result of premature pituitary stimulation and increased secretion of gonadotropins. The advent of magnetic resonance imaging (MRI) has made the diagnosis of central nervous system lesions more precise and accurate. Gonadotropin releasing hormone (GnRH) secreting hypothalamic hamartoma (HH) is the most common known cause of GDPP. It is a benign congenital malformation of the brain consisting of a heterotopic mass of nervous tissue that contains GnRH neurosecretory neurons. HH is usually situated in the posterior hypothalamus between the tuber cinereum and mamillary bodies or on the floor of the third ventricle.1,2

The goal of treatment in GDPP is to ensure the regression or arrest of secondary sexual characteristics and of skeletal maturation to preserve genetic height potential. Treatment with GnRH agonists (GnRH-a) induces down-regulation of luteinising hormone (LH) and follicle stimulating hormone (FSH) secretion, thereby suppressing the hypothalamic pituitary gonadal axis.3

Current data support the effectiveness and safety of GnRH-a treatment for GDPP, whether of the idiopathic type or secondary to HH.1 Side effects are reported rarely.4,5

We present long term clinical, radiological, and therapeutic data for eight children with GDPP due to HH.

Patients and methods
Eight patients with HH (five boys and three girls) had onset of pubertal signs between birth and therapeutic data for eight children with GDPP due to HH.

Table 1 Effects of GnRH-a treatment on clinical features, height standard deviation (SD) for chronological age, and height SD for bone age in GDPP due to hypothalamic hamartoma

<table>
<thead>
<tr>
<th>Patient</th>
<th>CA at onset of GnRH-a treatment (years)</th>
<th>Age at treatment (years)</th>
<th>Tanner stage</th>
<th>Height SD for CA</th>
<th>Height SD for BA</th>
<th>Tanner stage</th>
<th>Height SD for CA</th>
<th>Height SD for BA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.33</td>
<td>8.4</td>
<td>G2PH1</td>
<td>+0.21</td>
<td>G1PH1</td>
<td>−0.47</td>
<td>G1PH1</td>
<td>+1.37</td>
</tr>
<tr>
<td>2</td>
<td>1.91</td>
<td>3.4</td>
<td>G2PH2</td>
<td>+2.90</td>
<td>G1PH2</td>
<td>+2.24</td>
<td>G1PH2</td>
<td>+0.60</td>
</tr>
<tr>
<td>3</td>
<td>2.16</td>
<td>2.8</td>
<td>G2PH3</td>
<td>+0.20</td>
<td>G1PH3</td>
<td>+1.09</td>
<td>G1PH3</td>
<td>+0.68</td>
</tr>
<tr>
<td>4</td>
<td>1.16</td>
<td>3.6</td>
<td>G2PH1</td>
<td>+2.81</td>
<td>G1PH1</td>
<td>+1.16</td>
<td>G1PH1</td>
<td>+1.59</td>
</tr>
<tr>
<td>5*</td>
<td>2.5</td>
<td>5.0</td>
<td>B3PH1</td>
<td>+1.04</td>
<td>B3PH1</td>
<td>+3.11</td>
<td>B3PH1</td>
<td>+0.02</td>
</tr>
<tr>
<td>6</td>
<td>1.33</td>
<td>6.9</td>
<td>B4PH2</td>
<td>+3.0</td>
<td>B4PH2</td>
<td>−3.71</td>
<td>B4PH4</td>
<td>−0.51</td>
</tr>
<tr>
<td>7</td>
<td>1.83</td>
<td>4.1</td>
<td>B4PH3</td>
<td>+3.0</td>
<td>B4PH3</td>
<td>+3.52</td>
<td>B4PH3</td>
<td>+0.46</td>
</tr>
<tr>
<td>8</td>
<td>1.08</td>
<td>2.7</td>
<td>B2PH2</td>
<td>+1.04</td>
<td>B2PH2</td>
<td>−2.60</td>
<td>B1PH1</td>
<td>+3.10</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>1.66 (0.51)</td>
<td>4.61 (2.05)</td>
<td>+1.60 (1.27)</td>
<td>−0.92 (1.77)</td>
<td>+1.83 (1.54)</td>
<td>+1.11 (1.02)</td>
<td>+0.47 (3.52)</td>
<td>−0.02 (3.10)</td>
</tr>
<tr>
<td>Range</td>
<td>1.08 to 2.5</td>
<td>2.66 to 8.41</td>
<td>0.2 to 3.0</td>
<td>−3.71 to 1.46</td>
<td>+1.83 to 1.54</td>
<td>+1.11 to 1.02</td>
<td>−0.47 to 3.52</td>
<td>−0.02 to 3.10</td>
</tr>
</tbody>
</table>

*Case 5 was not included in the statistical analysis; p < 0.05 (baseline height SD for bone age + latest height SD for bone age).
CA, chronological age; BA, bone age; B, breast; PH, pubic hair; G, genitalia (testicular size), according to Tanner’s criteria.
Table 2  Peak GnRH stimulated concentrations of gonadotropin and sexual steroids in eight children with GDPP due to HH before and during treatment with GnRH-a.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Peak LH (IU/L)</th>
<th>Peak FSH (IU/L)</th>
<th>Testosterone (ng/dl)</th>
<th>Oestradiol (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>36*</td>
<td>1.7</td>
<td>18*</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>77</td>
<td>1.0</td>
<td>22</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>13</td>
<td>0.9</td>
<td>4</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>13</td>
<td>1.6</td>
<td>2</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>37*</td>
<td>23</td>
<td>13*</td>
<td>11</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>52*</td>
<td>1.5</td>
<td>9*</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>23</td>
<td>1.5</td>
<td>8</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>23</td>
<td>1.0</td>
<td>13</td>
<td>&lt; 1</td>
</tr>
</tbody>
</table>

*Radioimmunoassay.

Normal pubertal response LH peak after 100 µg of GnRH: for girls, >15 IU/l radioimmunoassay, > 7.0 IU/L immunofluorescent assay; for boys, > 25.5 IU/l radioimmunoassay, > 8.4 IU/l immunofluorescent assay.

Testosterone (ng/dl): prepubertal levels < 30 ng/dl (radioimmunoassay).

and 2 years of age. Pubertal development was evaluated according to Tanner’s criteria. 

Table 1 presents clinical features of these patients. No intellectual impairment, seizures, or behavioural disturbances were observed.

The GnRH stimulation test was done by administering 100 µg of intravenous GnRH (HRT, Wyeth-Ayerst; Maidenhead, Berkshire, UK) with blood samples for gonadotropin measurements obtained before and 15, 30, 45, and 60 minutes after injection. Plasma LH and FSH, testosterone, oestradiol, and dehydroepiandrosterone sulphate (DHEA-S) were measured by radioimmunoassay or immunofluorometric assay. We considered the response as pubertal when peak LH concentrations were > 7.0 IU/l for girls and > 8.4 IU/l for boys when measured by immunofluorometry, and peak LH > 15 IU/l for girls and > 25.5 IU/l for boys when measured by radioimmunoassay. The test was repeated every six months during treatment—immediately before a new GnRH-a administration for monitoring GnRH-a treatment. Adequate suppression during treatment was accepted if the peak values after GnRH were < 1.7 IU/l for LH and 2.5 IU/l for FSH according to Parker et al. Bone age was determined according to Greulich and Pyle. The neuroradiological assessment was done in all patients using MRI interpreted by the same radiologist (LSSL). All patients were treated with a GnRH-a, either goserelin (3.6 mg intramuscularly) or leuprolide acetate (3.75 mg subcutaneously), every four weeks.

STATISTICAL ANALYSIS

Comparison between height standard deviation (SD) for bone age at onset of treatment and the latest evaluation was analysed by Friedman test.

Results

The main problems in girls were premature breast development and menarche, whereas in boys they were pubic hair development, increased testicular size, and penile enlargement. Treatment with GnRH-a arrested or involuted sexual characteristics in seven of the eight patients. The hamartoma was attached in proximity to the tuber cinereum and mamillary bodies and extended into the suprasellar cistern in all patients. Hamartomas ranged in diameter from 5–18 mm. All patients had sessile masses. The duration of follow up with neuroimaging was 4–6 years in six patients. Neither the size nor the shape of the hamartoma changed over time in these patients.

All children had an initial pubertal response after their GnRH test (table 2). Treatment with GnRH-a suppressed basal and peak LH and FSH concentrations after GnRH administration in seven of eight patients.

The mean height SD for chronological age was +1.6 (1.27) at baseline and 1.83 (1.54) at the latest visit. The mean height SD for bone age increased significantly from −0.92 (1.77) to 1.11 (1.02) (p < 0.05) during GnRH treatment (table 1).

Six patients were treated with GnRH-a every four weeks with a good response. The treatment of patient 6 was changed to GnRH-a every three weeks because he presented with partial failure of hormone suppression and pubertal progression on standard treatment, with later arrest of pubertal signs.

One patient (case 5) presented with a severe local reaction at the injection site, resulting in induration and erythema followed by sterile abscess formation and treatment failure, which was characterised by progression of pubertal signs and bone age and non-suppressed testosterone and gonadotropin concentrations. He had been treated previously elsewhere with three different GnRH-a (leuprolide acetate, goserelin, and troyterol) over approximately four years with short acting and depot presentations and different forms of administration (daily, monthly) with poor outcome. When first seen in our clinic he was 7 years old with a bone age of 14 years and Tanner pubertal stage V. Testosterone concentrations and GnRH stimulated LH concentrations were high. He presented with local induration at the injection sites characterised by atrophy of subcutaneous tissue and nodule formation. We used another GnRH-a (goserelin) together with an antihistamine every four weeks for three months, but he again developed local induration with failure of hormone suppression, and has been treated subsequently with cyproterone acetate 75 mg/m².
Discussion

Hypothalamic and adjacent lesions are well described causes of precocious puberty and include hamartomas, gliomas, ependymomas, craniopharyngiomas, neurofibromas, tuberculous meningitis, suprasellar arachnoid cysts, and basilar artery aneurysms. Hypothalamic hamartomas are one of the most frequently cited causes of GDPP.12

The HH functions as an ectopic GnRH pulse generator that escapes the intrinsic central nervous system inhibitory mechanism which restrains the onset of puberty during the juvenile pause, thus resulting in GDPP. Patients with HH have physical signs of puberty indistinguishable from those with idiopathic GDPP.9

The diagnosis of GDPP due to HH is suggested by early onset of sexual precocity, generally before 2 years of age, especially if associated with gelastic seizures without focal neurological signs, in the presence of an isodense hypothalamic mass, seen on neuroimaging.

MRI is the imaging method of choice in the diagnosis of GDPP. The interpeduncular mass is well defined on computed tomography, but fine slices (2–3 mm width) in both axial and coronal planes should be used. The appearances on MRI are similar. The advantages of MRI over computed tomography are the avoidance of ionising radiation and iodine contrast medium and the possibility of obtaining clear visualisation in the sagittal as well as coronal and axial planes. The persistent grey matter intensity of the lesion in T1 and T2 weighted images indicated the homogeneous, neuronal nature of the masses.15 The most common presentation of HH was a small and well defined mass in the inferior side of the hypothalamus, showing isointensity on T1 weighted images and hyperintensity on T2 weighted images compared with the grey matter.2

MRI identified central nervous system lesions in 12 of 70 children with GDPP referred to the developmental endocrinology unit at the University of São Paulo medical school. Apart from the eight patients with HH reported here, two patients had arachnoid cysts, one meningomyelocele, and one neurofibromatosis with neurological signs, in the presence of an isodense hypothalamic mass, seen on neuroimaging.

Long term GnRH-a treatment was satisfactory in seven cases. All patients presented arrest or regression of secondary sexual characteristics, significant improvement of the mean SD height for bone age (table 1) and hormonal level suppression, as shown by basal and GnRH stimulated concentrations of LH at prepubertal levels (table 2). One boy presented with a local reaction followed by failure of hormonal suppression with progression of pubertal signs. The severe local reaction developed at the site of depot GnRH-a injection, followed by obvious escape from the intended gonadotropin suppression. The most likely cause of the local reaction is the biodegradable microcapsules made from a copolymer of lactic and glycolic acids (the “vehicle”). In these situations, investigators have increased the dosage in the hope that more drug will be absorbed, or the dose frequency is altered to every three weeks, although data do not exist to substantiate the efficacy of either strategy.14–16

The incidence of all types of clinically evident reactions to the depot GnRH-a injections is somewhat difficult to ascertain. Manasco et al cited 3–8% of children with local reactions.13 We have treated 70 patients with GDPP, using two long acting GnRH-a (leuprolide acetate or goserelin), and observed local reactions in one girl characterised by hyperaemia, and a severe local reaction in one boy.

In our study, none of the patients presented with neurological disorders. The hamartoma diameter of our patients ranged from 5–18 mm. Mahachoklertwattana et al reviewed the relation between the size of the HH and the occurrence of seizures, demonstrating that no patients with a hamartoma diameter of less than 10 mm had seizures; in contrast, all patients with a hamartoma of 25 mm or larger had seizures.

Late MRI evaluation in six of our cases showed stability of lesions in shape, size, and signal intensity. Surgical intervention in HH may be necessary in the rare instance of mass enlargement or compression of adjacent tissues causing progressive neurological deficit, hydrocephalus, or intractable seizures.1 6 13 17 A recent report concluded that total resection of an HH is the only surgical procedure that has a significant chance of reversing precocious puberty, and for pedunculated HH, total removal can be accomplished safely. Prolonged follow up of the two patients who underwent surgery showed that puberty reversal had not been complete, and permanent cure of the GDPP had not been achieved. The authors recommended that the initial management for a child with GDPP due to HH, even when it is pedunculated, should be clinical treatment with GnRH-a.18

We conclude that HH was the most frequent known cause of GDPP in our series, behaved benignly, and that GnRH-a treatment provided satisfactory and safe control of precocious pubertal development.


---

**FETAL AND NEONATAL EDITION**

**March Issue**

The following articles—being published in the March 1999 issue of the Fetal and Neonatal edition of Archives of Disease in Childhood—may be of particular general interest as they relate to community, social, and neurodevelopmental paediatrics.

**Visual function in term infants with hypoxic-ischaemic insults: correlation with neurodevelopment at 2 years of age**
Eugenio Mercuri, Leena Haataja, Andrea Guzzetta, Shirley Anker, Frances Cowan, Mary Rutherford, Rachel Andrew, Oliver Braddick, Giovanni Cioni, Lilly Dubowitz, Janette Atkinson

**Survival and place of delivery following preterm birth: 1994–96**
David Field, Elizabeth S Draper

**Trends in incidence of cranial ultrasound lesions and cerebral palsy in very low birthweight infants 1982–93**
Richard W J Cooke

**Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis**
Jacques Sarles, Sandrine Barthélémon, Claude Fère, Juan Iovanna, Michel Roussy, Jean-Pierre Farriaux, Amélie Toutain, Jacques Berthelot, Nicole Maurin, Jean-Pierre Godet, Patrice Berthézène, Jean-Charles Dagorn

**Prospective study of outcome in antenatally diagnosed renal pelvis dilatation**
Mervyn S Jawson, Loraine Dibble, Sheila Puri, Jacky Davis, Jane Young, Raj Dave, Heulwen Morgan

**Mortality from early onset group B streptococcal infection in the United Kingdom**
Nick Embleton, Unni Wariyar, Edmund Hey

**Unlicensed and off label drug use in neonates**
Sharon Conroy, John McIntyre, Imit Choonara

**“Sucrose analgesia”: absorptive mechanism or taste perception?**
Luca A Ramenghi, David J Evans, Malcolm I Levene

**BASIC SCIENCE**

**Plausible explanations for effects of long chain polyunsaturated fatty acids (LCPUFA) on neonates**
L O Karlak, T J Stephenson
Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot

Vinicius N de Brito, Ana C Latronico, Ivo J P Arnhold, Leonard S S Lo, Sorahia Domenice, Maria C C Albano, Maria C B V Fragoso and Berenice B Mendonca

Arch Dis Child 1999 80: 231-234
doi: 10.1136/adc.80.3.231

Updated information and services can be found at:
http://adc.bmj.com/content/80/3/231

These include:

References
This article cites 15 articles, 1 of which you can access for free at:
http://adc.bmj.com/content/80/3/231#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Oncology (777)
- Reproductive medicine (945)
- Sexual health (352)
- Clinical diagnostic tests (1133)
- Radiology (976)
- Radiology (diagnostics) (760)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/